# Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

> **NCT01158118** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 48 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Lymphoma, Non-Hodgkin
- Hodgkin Disease
- Leukemia, Lymphocytic, Chronic, B-Cell
- Multiple Myeloma

## Interventions

- **DRUG:** Sargramostim
- **DRUG:** Plerixafor

## Key facts

- **NCT ID:** NCT01158118
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-01
- **Primary completion:** 2014-01-15
- **Final completion:** 2016-12-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158118, "Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01158118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*